Arterial hypertension (HTN) and atrial fibrillation often coexist and the combination of these two conditions carries an increased risk of stroke. HTN is one of the most important risk factors included in the scores for stoke prediction in atrial fibrillation used to assess the need of anticoagulation, and HTN has also been strictly related to bleeding complications of antithrombotic therapy. Antithrombotic drugs options include vitamin K antagonists, or new oral anticoagulants, recently approved for stroke prevention in nonvalvular atrial fibrillation. More favorable new oral anticoagulant efficacy and safety, compared with warfarin, have been reported in hypertensive patients, making these drugs a first-line choice in this population to prevent cerebrovascular events and reduce the risk of major bleedings. The aim of this review is to explore the relationship among HTN, atrial fibrillation and the risk of stroke and to summarize the evidence on the impact of HTN on the choice of the most appropriate anticoagulation treatment.
INTRODUCTION
A trial fibrillation is the most common sustained cardiac arrhythmia and represents a major public health problem due to increased mortality risk, reduced quality of life, and increased health costs [1] . Several cardiovascular risk factors have been related to atrial fibrillation; however, high blood pressure (BP) is obviously one of the most common conditions that concur to atrial fibrillation manifestation, maintenance, and progression [2] . Data from the Framingham Heart Study, based on 38-year follow-up data, demonstrated that among cardiovascular risk factors, only hypertension (HTN) and diabetes were significant independent predictors of atrial fibrillation, adjusting for age and other predisposing conditions [3] . Moreover, the presence of HTN in patients also affected by atrial fibrillation is responsible for an increased risk of stroke [4] and influences the therapeutic management of this population.
The aim of this review is to provide updated evidence on the role of HTN in patients affected by atrial fibrillation and on the impact of HTN on the choice of anticoagulation treatment.
EPIDEMIOLOGY OF ATRIAL FIBRILLATION AND HYPERTENSION
High BP is a common condition in patients affected by atrial fibrillation. A position article of the Working Group 'Hypertension Arrhythmias and Thrombosis' of the European Society of Hypertension [5] reported that 49-90% of patients affected by atrial fibrillation also suffer arterial HTN. Moreover, the presence of HTN is strictly related to an increased risk to develop atrial fibrillation. In 1995, Krahn et al. [6] reported epidemiological data on atrial fibrillation incidence in 3983 male aircrew recruits, followed up for 44 years and analyzed the impact of 24 variables on the risk of atrial fibrillation. About 7% of patients developed atrial fibrillation with increasing incidence related to age, as already reported by an analysis of the Framingham Heart Study [3] . The prevalence of HTN was 53%, and an increased risk of atrial fibrillation of 1.42 times was observed in men with a history of HTN compared with normotensive patients. A more recent analysis of the Framingham cohort examined the 50-year trends in atrial fibrillation epidemiology in 9511 participants enrolled in the Framingham Heart Study between 1958 and 2007 [7] . In this study, HTN and its treatment carried the greatest population-attributable risk among all modifiable risk factors, and the authors recommended to intervene on modifiable risk factors, primarily HTN and BMI, as potential targets to prevent atrial fibrillation.
A recent meta-analysis [8] investigated the effects of antihypertensive therapy on atrial fibrillation onset examining 27 trials with 214 763 randomized participants and 9929 atrial fibrillation events. The authors reported that antihypertensive treatment reduced the risk of atrial fibrillation by 10% [relative risk (RR) 0.90; confidence interval (CI) 0.86-0.94] in the whole hypertensive population. However, this effect was significantly more evident in patients affected by heart failure (RR 0.81; CI 0.74-0.87) than in patients with coronary heart disease but no heart failure (RR 0.95; CI 0.89-1.01) or patients with no previous heart disease (RR 1.02; CI 0.88-1.18). The greatest effect observed in heart failure patients could be either due to a specific physiological response or to a higher baseline risk for atrial fibrillation development in this population [9] . Notably, comparing classes of medication against each other, no significant differences on atrial fibrillation occurrence were found [8] . In fact, uncertainty still exist about the effects of different drugs' classes in primary or secondary prevention of atrial fibrillation events. A previous metaanalysis [10] analyzed the impact of the renin-angiotension system (RAS) inhibition on atrial fibrillation prevention reporting data from 23 randomized controlled trials including 87 048 patients. Overall, RAS inhibition reduced the odds ratio for atrial fibrillation by 33% (P < 0.00001), but substantial heterogeneity among trials were found and some reports were based on post-hoc analyses. In addition, in primary prevention, RAS inhibition resulted effective in patients with heart failure and those with HTN and left ventricular (LV) hypertrophy (LVH), but not in postmyocardial infarction patients.
ATRIAL FIBRILLATION AND TARGET ORGAN DAMAGE
A strict relationship has been reported between target organ damage (TOD) associated with HTN and atrial fibrillation occurrence, and the increased risk of atrial fibrillation that HTN portends is further amplified in the case of HTNrelated TODs. In particular, baseline severity of LVH has been demonstrated to be an additional predictor of atrial fibrillation by several authors. In the LIFE study [11] , age (9% higher rate for each year of age), male sex (56% increase in risk compared with women), SBP (6% increase per 10 mmHg), and LVH by Cornell product at ECG analysis (4% increase per 100 mV ms) were significantly related to the risk of new-onset atrial fibrillation. The PIUMA study [12] followed up for 16 years 2482 initially untreated patients with HTN; a first episode of atrial fibrillation occurred in 61 patients at a rate of 0.46 per 100 personyears. Age and echocardiographic LV mass were the only independent predictors of atrial fibrillation and for every 1 SD (14 g/height 2.7) increase in LV mass, the risk of atrial fibrillation increased by 1.73 times (95% CI 1.34-2.24). These findings, taken together with the greater reduction in Cornell product LVH observed in a subanalysis of the LIFE study in losartan-based therapy [13] and the reduction in cardiovascular morbidity and mortality associated with LVH regression reported in previous studies [14] , suggest that regression of LVH may be relevant in the prevention of atrial fibrillation in patients affected by HTN. In fact, regression of LVH, assessed by Cornell product during antihypertensive therapy, has been associated with a lower likelihood of new-onset atrial fibrillation as compared with persistent hypertrophy, independent on BP lowering [15] . Thus, a strict control of BP, aimed also at preventing the progression of TOD, might be a reasonable approach to reduce atrial fibrillation risk in hypertensive patients.
HYPERTENSION AND STROKE
HTN is considered the most important risk factor for stroke (either ischemic or hemorrhagic) in the general population. An analysis of 27 936 patients living in Sweden [16] reported a crude incidence of stroke of 289/100 000 person-year in controlled hypertensive patients and of 705/100 000 person-year in treated hypertensive patients with BP more than 140/90 mmHg. Moreover, the population-attributable risk indicated that 45% (with age-adjusted and sex-adjusted RR) or 52% (with unadjusted RR) of strokes in patients on treatment for HTN might be attributed to uncontrolled BP, and the great majority of stroke patients (88-100%), irrespective of subtypes, had uncontrolled BP.
Atrial fibrillation per-se accounts for a three-fold to sixfold increase in stroke risk compared with the general population [1, 17] ; when atrial fibrillation and HTN coexist, HTN increases stroke rate by an additional two-fold to three-fold [18, 19] . Lip et al. [20] reported in a cross-sectional, longitudinal analysis, performed using data from the SPOR-TIF III, and V trials, an increasing rate of stroke and systemic embolism with increasing quartiles of SBP in atrial fibrillation patients. In particular, the top quartile of SBP (140.8-191.7 mmHg) was associated with a greater risk of stroke and systemic embolism than the lowest quartile (84.0-122.6 mmHg) [hazard ratio (HR) 1.83; 95% CI 1.22-2.74], whereas mortality was lower in the top quartile (HR 0.64; 95% CI 0.49-0.83). The event rate for stroke/systemic embolism increased markedly at mean SBP of 140 mmHg, supporting SBP as being a more powerful risk factor of stroke among atrial fibrillation patients compared with DBP.
Thus, HTN is one the most important risk factors included in the clinical scores for stoke prediction in atrial fibrillation patients used to assess the need of anticoagulation therapy. In 2001, the cardiac failure, HTN, age, diabetes, stroke (doubled) (CHADS 2 ) score was validated as an easy-to-use classification scheme to estimate the risk of stroke in atrial fibrillation [21] , then in 2010 the congestive heart failure, HTN age at least 75 (doubled), diabetes, stroke (doubled), vascular disease, age 65-74, and sex category (female) (CHA 2 DS 2 -VASc) score has been proposed as an improvement to the CHADS 2 for risk discrimination of lower risk patients [22] . The most recent guidelines on atrial fibrillation management [23, 24] recommend for patients with nonvalvular atrial fibrillation with prior stroke, transient ischemic attack, or a CHA 2 DS 2 -VASc score of 2 or greater, oral anticoagulant therapy to prevent the risk of stroke or systemic embolic events. However, controversies still exist about the treatment of patients with a CHA 2 DS 2 -VASc score of 1. The 2012 update of the European guidelines [23] reported that in patients with a CHA 2 DS 2 -VASc score of 1, oral anticoagulation therapy should be considered, based upon the assessment of the risk of bleeding complications and patient preferences. Thus, from this point of view, the presence of HTN in atrial fibrillation patients might be sufficient to start antithrombotic treatment. On the other hand, American guidelines [24] state that no antithrombotic therapy or treatment with an oral anticoagulant or aspirin is recommended in this class of patients, not solving the doubts concerning the risk-benefit ratio of anticoagulant therapy in these patients. The main problem is the true risk of stroke in this population, as stroke risk estimates for atrial fibrillation patients with a CHA 2 DS 2 -VASc score of 1 and no antithrombotic treatment varies from 0.6 to more than 2.0% in different studies [25] [26] [27] . Friberg et al. [28] recently conducted a retrospective study of 140 420 patients with atrial fibrillation in Swedish nationwide health registries to assess atrial fibrillation-related stroke risk among patients with a CHA 2 DS 2 -VASc score of 1. The authors reported that this risk seems to be lower than previously reported. In particular, they found that the annual event rates varied between 0.5 and 0.9%, depending on whether only ischemic strokes were considered or a more inclusive endpoint of stroke, transient ischemic attack, and various forms of systemic embolism was used. For women, annual stroke rates varied between 0.1 and 0.2%, and for men from 0.5 to 0.7%, concluding that no benefit is expected for routine administration of anticoagulant agents to these patients [28] . On the contrary, a simultaneous study from Lip et al. [29] on 39 400 Danish patients discharged with incident nonvalvular atrial fibrillation and 0 or 1 CHA 2 DS 2 -VASc score reported that about 50% of patients with 1 risk factor had age as the only risk factor (>65 years), and 90% had either age or HTN as the main risk factors. Stroke event rates for untreated low-risk patients [CHA 2 DS 2 -VASc ¼ 0 (man), 1 (woman)] were 0.49 per 100 person-years at 1 year and 0.47 per 100 personyears at full follow-up (intention-to-treat; 5.9 years). In addition, the presence of one additional risk factor increased the stroke event rates at 1 year to 1.55 per 100 person-years, representing a significant 3.01-fold increase for patients receiving no treatment. A previous study by Huang et al. [30] in a cohort of 9727 Chinese atrial fibrillation patients reported an annual incidence of stroke of 2.4 and 6.6% for patients with CHA 2 DS 2 -VASc score of 0 and 1, respectively, showing that patients with HTN were at the highest risk of stroke (HR 9.8, 95% CI 2.7-35.6), followed by patients aged 65-74 (HR 3.9, 95% CI 2.3-6.6) and female sex (HR 2.3, 95% CI 1.1-4.8). Thus, anticoagulation treatment might be justified among atrial fibrillation patients with CHA 2 DS 2 -VASc score of 1 due to HTN.
Women generally have lower age-adjusted prevalence of atrial fibrillation than men; however, given the longer life expectancy, the absolute number of men and women with atrial fibrillation is similar, and female sex has been demonstrated to be a risk factor for atrial fibrillation-related stroke or thromboembolic events [31] . However, recommendations on anticoagulation treatment in low-risk patients are mainly based on nongender-related CHA 2 DS 2 -VASc score [32] since the link between female sex and stroke might vary between populations and age groups. Thus, female sex as isolated risk factor does not justify anticoagulation treatment. In particular, female patients might be at substantial higher risk of stroke only when aged more than 75 years, thus already presenting a CHA 2 DS 2 -VASc score of at least 2 [33] . However, anticoagulated, female patients with atrial fibrillation show a similar rate of cardiovascular death and stroke/systemic embolism, but a lower risk of major bleeding, compared with men [34] .
IMPACT OF HYPERTENSION ON ANTICOAGULATION THERAPY
In hypertensive patients with atrial fibrillation, the impact of HTN on antithrombotic drugs complication should always be considered. Before oral anticoagulant therapy is started, the HTN abnormal renal/liver function, stroke, bleeding history or predisposition, Labile INR, elderly (e.g. age 0.65, frailty, etc.), drugs/alcohol concomitantly (HAS-BLED) score need to be calculated to define the net clinical benefit of treatment [23, 24] . Of course, HTN is included as a major risk factor for bleeding events, but, at variance with the thrombotic score, the hemorrhagic score takes into account the actual value of SBP (if !160 mmHg) rather than the condition of HTN by itself. This represents quite a substantial yet underperceived difference, as it should prompt clinicians to strictly control HTN, as well as other reversible hemorrhagic risk factor, to reduce bleeding risk.
In fact, HTN has been strictly related to bleeding complications of antithrombotic therapy. In 1995, Hart et al. [35] reported that anticoagulation to conventional intensities increases the risk of intracranial hemorrhage seven-fold to 10-fold and independent predictors of anticoagulantrelated intracerebral hematoma were advanced age, prior ischemic stroke, HTN, and intensity of anticoagulation. Similarly, in a study by Launbjerg et al. [36] , 1010 patientyears of oral anticoagulant therapy with vitamin-Kantagonists were reviewed with regard to major bleeding complications. The incidence of bleeding that required hospital admission was 2.7%/year, predominantly related to the alimentary tract, whereas no cases of intracranial bleeding were observed. At multivariate statistical analysis, age more than 75 years and HTN were found to be independent predictors of major bleeding complications, increasing the bleeding risk by 10.5 and 4.5%, respectively. A recent analysis of the randomized evaluation of long-term anticoagulation therapy (RE-LY) study [37] reported that patients with HTN had a greater risk of major bleeding (3.39 vs 2.76%; P ¼ 0.0068), but a similar risk of intracranial bleeding (0.47 vs 0.31%; P ¼ 0.1174) compared with patients without HTN. In addition, analysis from the SPOR-TIF III and V trials [20] reported an increased event rate for hemorrhagic stroke with increasing quartiles of BP (P for Q1 þ 2 vs Q3 þ 4 was 0.013), with a total number of events of 1 (0.04%/year), 2 (0.07%/year), 5 (0.17%/year), and 9 (0.32%/year) in the four SBP quartiles. The event rate of major bleedings was near 2%/year with no differences among SBP quartiles. Thus, HTN not only accounts for an increased risk of stroke but is also associated with an increased incidence of major bleeding during anticoagulation therapy.
However, despite several relevant evidences on the relationship between atrial fibrillation and HTN, BP data remain not adequately considered in atrial fibrillation trials. In particular, in these studies very limited data are provided concerning BP control during the trial and antihypertensive treatment at enrollment. In particular, in an interesting revision on this topic, Manolis et al. [38] suggested that BP data, that is, initial and final BP values, BP control during study, and type of treatment, should be regularly included in all future studies with antithrombotic therapy, also adjusting outcomes (including bleedings) for BP-related variables.
ANTICOAGULATION TREATMENT IN HYPERTENSION PATIENTS
Antithrombotic drugs options actually include vitamin K antagonists, in particular warfarin, in use since the 1950s for stroke prevention in patients with atrial fibrillation, or new oral anticoagulants (NOACs), including dabigatran, apixaban, rivaroxaban, and edoxaban, recently approved for stroke prevention in nonvalvular atrial fibrillation. Selection of antithrombotic agents depends on several factors, including clinical characteristics, presence of comorbidities, patient preference, and costs. NOACs have the great advantage to not require regular monitoring of coagulation parameters, whereas dose adjustments may be warranted for patients affected by chronic kidney disease or low body weight, making the therapeutic management more practical especially in elderly patients. All NOACs share additional clinical advantages over warfarin due to better known and reproducible pharmacological profiles, fewer drugs-todrugs interactions, absence of dietary effects, and substantially reduced risk of intracranial bleeding compared with warfarin.
The trials that compared NOACs with warfarin for prevention of stroke and systemic embolism in atrial fibrillation patients included high percentages of patients affected by HTN, reporting similar benefits of NOACs in patients with and without HTN at baseline. In particular, in the RE-LY [39] study, that compared dabigatran with warfarin, about 80% of patients exhibited HTN; similarly, the ROCKET-AF (The Rivaroxaban Once Daily Oral Direct Factor Xa Inhibition Compared with Vitamin K Antagonism for Prevention of Stroke and Embolism Trial in Atrial Fibrillation) study [40] reported a prevalence of HTN of about 90%, whereas in the ARISTOTLE (Apixaban for Reduction in Stroke and Other Thromboembolic Events in Atrial Fibrillation) study [41] prevalence of HTN was 86%; finally, in the ENGAGE-AF (The Effective Anticoagulation with Factor Xa Next Generation in Atrial Fibrillation) [42] that compared edoxaban vs warfarin, 93% of patients were also affected by HTN requiring pharmacological treatment. The RE-LY study [39] demonstrated that a dose of dabigatran of 110 mg was associated with similar rates of stroke and systemic embolism compared with warfarin (P < 0.001 for noninferiority); however with dabigatran lower rates of major hemorrhage (P ¼ 0.003) and lower rates of hemorrhagic strokes (P < 0.001) were observed. Dabigatran administered at a dose of 150 mg, compared with warfarin, was associated with lower rates of stroke and systemic embolism (P < 0.001 for superiority) and, in particular of hemorrhagic strokes (P < 0.001), but similar rates of major bleeding (P ¼ 0.31) were observed. A subanalysis of the RE-LY study [37] compared the baseline characteristics and outcomes in patients with and without HTN enrolled in the study. The authors reported that patients with HTN had a greater prevalence of diabetes were more likely to be woman, and showed greater CHADS 2 and CHA 2 DS 2 -VASc scores compared with nonhypertensive patients. No significant differences were found in the risk of stroke or systemic embolism between patients with and without HTN (1.49 vs 1.31%; P ¼ ns); however, hypertensive patients exhibited a greater risk of major bleeding, in spite of excellent BP control during the trial, but a similar risk of intracranial bleeding compared with patients without HTN. The increase in mean and SBP was associated with an increased risk of stroke and systemic embolism; a 6%-fold to 7%-fold increased risk for every 10 mmHg increase in mean (P ¼ 0.046) and SBP (P ¼ 0.016) was reported, whereas the increase in DBP was not related to a significantly increased risk of stroke (P ¼ 0.47). Regarding dabigatran effects, both benefits and safety compared with warfarin were similar in patients with and without HTN (P interaction 0.06 for 110 mg; P interaction 0.58 for 150 mg), confirming the beneficial effects in this subgroup of patients exposed to an increased risk of hemorrhagic events. The ROCKET-AF study [40] reported that rivaroxaban was noninferior to warfarin for the prevention of stroke or systemic embolism with no differences between hypertensive and nonhypertensive patients [43] . Nonmajor clinically relevant bleedings showed similar rates (P ¼ 0.44); however, rivaroxaban exhibited a better safety profile compared with warfarin for intracranial bleeding (0.5 vs 0.7%; P ¼ 0.02) and fatal bleeding (0.2 vs 0.5%; P ¼ 0.003). An analysis of the Japanese patients enrolled in the ROCKET-AF trial [44] showed that the safety and efficacy profile of rivaroxaban were similar to that of warfarin, independent of baseline hypertensive status.
In the ARISTOTLE trial [41] , apixaban given twice daily at the dose of 5 mg significantly reduced the primary endpoint of ischemic or hemorrhagic stroke or systemic embolism, with an overall rate of major bleeding of 2.13%/year in the apixaban group, compared with 3.09%/year in the warfarin group (HR 0.69; 95% CI 0.60-0.80; P < 0.001). A recent analysis from the same trial [45] demonstrated that the risk of stroke or systemic embolism was higher in patients with a history of HTN (HR 1.33; 95% CI 1.00-1.76) or with elevated BP at study entry (HR 1.24; 95% CI 1.03-1.49). In addition, elevated BP at any point during the study were significantly related with increased risk of stroke or systemic embolism (HR 1.53; 95% CI 1.25-1.86) and of hemorrhagic stroke (HR 1.85; 95% CI 1.26-2.72). The favorable effects of apixaban, compared with warfarin, in preventing stroke or systemic embolism were consistent among patients with and without HTN (P interaction ¼ 0.27), elevated BP at study entry (P interaction ¼ 0.43), and elevation in BP during the trial (P interaction ¼ 0.97) [45] . Finally, the ENGAGE-AF study [42] demonstrated that edoxaban, in both once-daily regimens, was noninferior to warfarin for the prevention of stroke or systemic embolism with a better safety profile compared with warfarin. In particular, the annualized rate of major bleeding was 3.43% with warfarin vs 2.75% with edoxaban 60 mg (HR 0.80; 95% CI 0.71-0.91; P < 0.001) and 1.61% with 30 mg edoxaban (HR 0.47; 95% CI 0.41-0.55; P < 0.001). Once again, no differences were found among patients with or without HTN for efficacy (P interaction 0.09 for 60 mg) and safety (P interaction 0.068 for 60 mg) [43] . Therefore, as recently reported by a document published to assist clinical decision regarding anticoagulants [43] , in HTN patients HRs for NOACs, compared with warfarin, vary from 0.69 to 0.80 for safety and 0.64 to 0.84 for efficacy, making HTN patients candidate for NOACs.
Currently, head-to-head trials among NOACs are not available, thus cautioning on meaningful comparison among different NOACs. In fact, indirect comparison would be inappropriate in light of the different clinical characteristics, as well as thromboembolic and hemorrhagic risk profiles, of patients populations enrolled in major clinical trials [46] . Yet, meta-analyses have addressed the efficacy and safety of NOACs in particular subset of patients. Ruff et al. [47] performed a comprehensive meta-analysis of all 71 683 participants included in the RE-LY [39] , ROCKET-AF [40] , ARISTOTLE [41] , and ENGAGE-AF [42] trials addressing the relative benefit of NOACs in key subgroups. The authors observed, in high-dose NOACs analysis, that allocation to a NOAC significantly reduced the composite of stroke or systemic embolic events by 19% compared with warfarin, despite significant differences in underlying risk for stroke across the trials with a 14% nonsignificant reduction in major bleedings. The low-dose NOACs regimens showed similar efficacy to warfarin for the composite of stroke or systemic embolic events and, as observed for high-dose regimens, also a significant reduction in all-cause mortality. Again, nonsignificant reduction in major bleeding was observed, but significant reduction in intracranial hemorrhage was reported. The benefit of NOACs in reducing stroke or systemic embolic events was consistent across all subgroups examined. Although a subgroup analysis for HTN was not reported, the efficacy and safety advantages of NOACs over warfarin were consistent across major subgroups of patients, including elderly, patients with chronic kidney disease and those with previous stroke, in whom HTN is a highly prevalent comorbidity. These benefits also extend to particularly high cardiovascular risk patients as those with heart failure and atrial fibrillation, as reported in a recent meta-analysis including subgroups of patients with heart failure enrolled in the four major NOACs clinical trials [48] .
Recently, Morimoto et al. [49] performed a network meta-analysis comparing different NOACs and mostly confirmed a comparable efficacy and safety profile of NOACs, although no separate analysis for HTN patients was performed.
Thus, there is no evidence for choosing a particular NOACs based on the presence of HTN, and indications are that 'no particular NOAC is superior to another NOAC in terms of safety or efficacy in patients with atrial fibrillation and HTN' [43] .
CONCLUSION
HTN and atrial fibrillation commonly coexist and their combination carries an increased risk of stroke and systemic embolism. Poorly controlled BP in the context of anticoagulated atrial fibrillation patients is associated with an increased risk of bleeding complications. Hence, presence and severity of HTN and quality of BP control should always be considered in anticoagulated patients to minimize bleeding side effects. Independently on HTN treatment and control, more favorable efficacy and safety of NOACs, compared with warfarin, have been reported in HTN patients, making NOACs recommendable as a firstline choice in this population to prevent cerebrovascular events and reduce the risk of major bleeding.
Reviewer's Summary Evaluations

Reviewer 1
Arterial hypertension is associated with 1.8-fold increased risk of developing new-onset atrial fibrillation (AF) and 1.5-fold risk of progression to permanent AF, while it is likely to be also a reversible causative factor of AF. Both of these entities may confer on serious cardiovascular outcomes. Awareness of this increased risk warrants a closer follow-up of these patients. Thus, treatment of atrial fibrillation with appropriate regimens (choosing also the most appropriate anticoagulation treatment) and control of the levels of blood pressure levels is imperative in order to improve cardiovascular morbidity and mortality.
